Paloma Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Paloma Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-520	Closed	-$123K	–	2524
2017 Q2	$123K	Buy	+520	New	+$118K	﹤0.01%	2059
2014 Q3	–	Sell	-60	Closed	-$434K	–	1344
2014 Q2	$434K	Buy	+60	New	+$300K	0.02%	645

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paloma Partners's EIGR Position: Q3 2017 in Review

Paloma Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 520 shares — an estimated $123K sold.

Paloma Partners first reported a position in EIGR in Q2 2014 and held it in 2 quarters. The position peaked at $434K in Q2 2014. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

Paloma Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 520 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $123K.
Paloma Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
Paloma Partners's Eiger BioPharmaceuticals, Inc. position peaked at $434K in Q2 2014.
33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.